Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee

Wedbush Remains Bullish on Carbylan Therapeutics (CBYL) Despite Mixed Cor1.1 Results - PT to $14

February 2, 2016 1:49 PM EST

Wedbush reiterated an Outperform rating on Carbylan Therapeutics (NASDAQ: CBYL), and raised the price target to $14.00 (from $21.00). Carbylan announced that Hydros-TA missed on the second primary endpoint of demonstrating a statistically significant improvement in pain scores at week 26 vs. TA. Wedbush anticipates that once Carbylan completes its analysis of COR1.1, management will likely meet... More